Mirum Pharmaceuticals Price Target Raised to $116.99
ByAinvest
Wednesday, Feb 4, 2026 4:32 pm ET1min read
MIRM--
Mirum Pharmaceuticals' (MIRM) average one-year price target has been revised to $116.99/share, a 10.50% increase from the prior estimate of $105.88. The price target is an average of many targets provided by analysts, ranging from $95.95 to $147.00/share. The fund sentiment indicates a bullish outlook with 464 funds or institutions reporting positions in MIRM. The average portfolio weight of all funds dedicated to MIRM is 0.30%, and total shares owned by institutions increased by 2.30% to 68,396K shares in the last three months.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet